Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-401-OTS in relapsed AML and MDS
NCT06552416Phase 1Recruiting
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Sep 2029
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MT-401 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 cohorts), sponsored by Marker Therapeutics, Inc. Primary endpoints: Safety of MT-401-OTS at 5 years and Tolerability of MT-401-OTS at 5 years. Started Jun 2025; status: recruiting.
02
Drugs
MT-401
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06552416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552416.